%0 Journal Article
%A Causa, Roberta
%A Almagro-Nievas, Diego
%A Rivera-Izquierdo, Mario
%A Benitez-Munoz, Nicolas
%A Lopez-Hernandez, Begona
%A Garcia-Garcia, Fernando
%A Alvarez-Estevez, Marta
%A Soto-Perez, Maria De la O.
%A Bermudez-Tamayo, Clara
%T Antibody Response 3 Months after 2 Doses of BNT162b2 mRNA COVID-19 Vaccine in Residents of Long-Term Care Facilities
%D 2021
%@ 0304-324X
%U https://hdl.handle.net/10668/25999
%X Background: Older adults living in long-term care facilities (LTCFs) are at increased risk for severe outcomes from COVID-19 and were identified as a priority group in COVID-19 vaccination strategies. Emerging evidence suggests vaccine effectiveness in LTCF populations, but data about median and long-term durability of immune response after vaccination are still limited. Objectives: In this study, we assessed the humoral response to BNT162b2 mRNA COVID-19 vaccine 3 months after the second dose, in a cohort of 495 residents aged >= 65 years from 11 LTCF in Granada, Spain. Method: Between April 19 and April 30, 2021, we measured anti-SARS-CoV-2 Spike IgG to evaluate the humoral vaccination response. Antibody titers were reported in binding antibody units (BAU/mL). Bivariate and multivariate logistic regression models were performed to investigate the impact of age, sex, underlying health conditions, and prior COVID-19 infection on the antibody levels. Results: Over 96% of the participants developed an adequate humoral response. We detected higher antibody titers in previously infected individuals, compared with those previously uninfected (B: 1,150.059 BAU/mL, p = 65 years from 11 LTCF in Granada, Spain. Method: Between April 19 and April 30, 2021, we measured anti-SARS-CoV-2 Spike IgG to evaluate the humoral vaccination response. Antibody titers were reported in binding antibody units (BAU/mL). Bivariate and multivariate logistic regression models were performed to investigate the impact of age, sex, underlying health conditions, and prior COVID-19 infection on the antibody levels. Results: Over 96% of the participants developed an adequate humoral response. We detected higher antibody titers in previously infected individuals, compared with those previously uninfected (B: 1,150.059 BAU/mL, p
%K COVID-19
%K Antibody response
%K Long-term care facilities
%K BNT162b2
%K Immunosenescence
%~